Björn Nashan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1238941/publications.pdf

Version: 2024-02-01

		361413	330143
82	1,650 citations	20	37
papers	citations	h-index	g-index
83	83	83	3485
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Early Everolimusâ€Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial. Liver Transplantation, 2022, 28, 998-1010.	2.4	15
2	Postmortem high-dimensional immune profiling of severe COVID-19 patients reveals distinct patterns of immunosuppression and immunoactivation. Nature Communications, 2022, 13, 269.	12.8	16
3	Liver Transplantation Reverses Hepatic Myelopathy in Hepatitis B-Related Decompensated Liver Cirrhosis: Case Report and Review of the Literature. Transplantation Proceedings, 2022, 54, 158-160.	0.6	4
4	Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model. Cancers, 2022, 14, 1882.	3.7	6
5	Porcine cytomegalovirus in xenotransplantation: The new frontier in human transplantation?. , 2022, 1, $11\text{-}13$.		1
6	Effect of everolimusâ€based drug regimens on CMVâ€specific Tâ€cell functionality after renal transplantation: 12â€month ATHENA subcohortâ€study results. European Journal of Immunology, 2021, 51, 943-955.	2.9	9
7	C20orf204, a hepatocellular carcinoma-specific protein interacts with nucleolin and promotes cell proliferation. Oncogenesis, 2021, 10, 31.	4.9	12
8	Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. American Journal of Transplantation, 2021, 21, 2833-2845.	4.7	27
9	An Orthotopic Liver Transplantation Patient Survived Without Hepatic Artery Flow Due to Thrombosis: A Case Report. Transplantation Proceedings, 2021, 53, 1295-1299.	0.6	1
10	Successful, Combined Long-term Treatment of Cerebral Candidiasis and Aspergillosis in a Liver Transplant Recipient: A Case Report. Transplantation Proceedings, 2021, 53, 2588-2593.	0.6	3
11	Innate lymphoid cells and cancer: Role in tumor progression and inhibition. European Journal of Immunology, 2021, 51, 2188-2205.	2.9	22
12	Diagnostic and Prognostic Significances of SOX9 in Thymic Epithelial Tumor. Frontiers in Oncology, 2021, 11, 708735.	2.8	15
13	Reduced Opioid-Demand and Fewer Pulmonary Complications after Laparoscopic Liver Resection in the Posterior Segments. Digestive Surgery, 2020, 37, 129-134.	1.2	6
14	Protein tyrosine phosphatase nonâ€receptor type 22 (PTPN22) gene polymorphisms in liver transplant donors and impact on acute cellular liver transplant rejection. Hla, 2020, 95, 40-44.	0.6	1
15	Sequential metastasis to the liver and pancreas 4 years after gestational trophoblastic neoplasia: a case report. Journal of International Medical Research, 2020, 48, 030006052096680.	1.0	O
16	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	3.3	4
17	CD28 gene polymorphisms and acute cellular rejection after liver transplantation. Human Immunology, 2020, 81, 675-678.	2.4	1
18	Liver Transplantation in a Patient With Acute-on-Chronic Liver Failure Due to Traditional Chinese Medicine Intoxication Using Donation After Circulatory Death From a Renal Transplant Recipient: A Case Report. Transplantation Proceedings, 2020, 52, 2813-2816.	0.6	1

#	Article	IF	CITATIONS
19	Transplantation of a single kidney from pediatric donors less than 10 kg to children with poor access to transplantation: a two-year outcome analysis. BMC Nephrology, 2020, 21, 250.	1.8	9
20	Incidence and potential predictors of thromboembolic events in epithelial ovarian carcinoma patients during perioperative period. European Journal of Surgical Oncology, 2020, 46, 855-861.	1.0	18
21	Ectonucleoside triphosphate diphosphohydrolase 1 and 5′â€nucleotidase ecto gene polymorphisms and acute cellular rejection after liver transplantation. Hla, 2020, 96, 64-69.	0.6	O
22	Novel coronavirus (SARS-CoV-2) infection in a renal transplant recipient: Case report. American Journal of Transplantation, 2020, 20, 1864-1868.	4.7	67
23	Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older. European Journal of Gynaecological Oncology (discontinued), 2020, 41, 415.	0.2	0
24	228â€Risk factors for preoperative complications and management with enhanced recovery after primary surgery for women with epithelial ovarian cancer in a single center of china., 2020,,.		0
25	ATHENA VS HEPHAISTOS - ARE DISCONTINUATION RATES IN MULTICENTER STUDIES DRIVEN BY FACTS OR ATTITUDES?. Transplantation, 2020, 104, S627-S627.	1.0	0
26	Structured introduction of retroperitoneoscopic donor nephrectomy provides a high level of safety and reduces the physical burden for the donor compared to an anterior mini incision: A cohort study. International Journal of Surgery, 2019, 69, 139-145.	2.7	2
27	CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans. Frontiers in Immunology, 2019, 10, 1247.	4.8	11
28	The incidence and severity of post-hepatectomy bile leaks is affected by surgical indications, preoperative chemotherapy, and surgical procedures. Hepatobiliary Surgery and Nutrition, 2019, 8, 101-110.	1.5	26
29	Effects of LncRNA Lnc-LIF-AS on cell proliferation, migration and invasion in a human cervical cancer cell line. Cytokine, 2019, 120, 165-175.	3.2	6
30	An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in deÂnovo kidney transplant patients. Kidney International, 2019, 96, 231-244.	5.2	69
31	Impact of TBX21, GATA3, and FOXP3 gene polymorphisms on acute cellular rejection after liver transplantation. Hla, 2019, 93, 97-101.	0.6	3
32	Donor derived HLA-G polymorphisms have a significant impact on acute rejection in kidney transplantation. Human Immunology, 2019, 80, 176-183.	2.4	10
33	Limited impact of pre-existing donor specific HLA-antibodies (DSA) on long term allograft survival after first adult liver transplantation. Human Immunology, 2018, 79, 545-549.	2.4	6
34	Outcome and natural course of renal dysfunction in liver transplant recipients with severely impaired kidney function prior to transplantation. United European Gastroenterology Journal, 2018, 6, 104-111.	3.8	19
35	The Authors' Reply. Transplantation, 2018, 102, e83-e84.	1.0	4
36	The killer cell lectinâ€like receptor B1 (KLRB1) 503T>C polymorphism (rs1135816) and acute rejection after liver transplantation. Hla, 2018, 91, 52-55.	0.6	3

#	Article	IF	Citations
37	mTOR Inhibition and Clinical Transplantation. Transplantation, 2018, 102, S19-S26.	1.0	16
38	The Athena Study. Transplantation, 2018, 102, S279.	1.0	1
39	CD40 Inhibition with CFZ533 - A New, Fully Human, Non-Depleting, Fc Silent mAB - Improves Renal Allograft Function While Demonstrating Comparable Efficacy vs. Tacrolimus in De-Novo CNI-Free Kidney Transplant Recipients. Transplantation, 2018, 102, S366.	1.0	5
40	Significant Anti-CMV/BKV Effect of a Modern Everolimus-Based Regimen Comparted to Standard Tacrolimus-MPA Regimen in de Novo Kidney Transplant Recipients. Transplantation, 2018, 102, S128.	1.0	1
41	Outcomes on Allograft Function after 12 Months with Everolimus Plus either Tacrolimus or Cyclosporine Compared to a Standard Tacrolimus-MPA Regimen in De Novo Renal Transplant Recipients. Transplantation, 2018, 102, S280.	1.0	1
42	Outcome following rightâ€extended split liver transplantation in the recent transplant era: Singleâ€center analysis of a German transplant center. Clinical Transplantation, 2018, 32, e13288.	1.6	7
43	Segment 5 parenchymal sparing in extended left hepatectomy with respect to venous outflowâ€"is it a feasible procedure?. Langenbeck's Archives of Surgery, 2018, 403, 663-670.	1.9	0
44	Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy. Transplantation, 2017, 101, 2612-2620.	1.0	23
45	Improved detection of alcohol consumption using the novel marker phosphatidylethanol in the transplant setting: results of a prospective study. Transplant International, 2017, 30, 611-620.	1.6	52
46	The influence of PEEP and positioning on central venous pressure and venous hepatic hemodynamics in patients undergoing liver resection. Journal of Clinical Monitoring and Computing, 2017, 31, 1221-1228.	1.6	14
47	Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation. Pancreatology, 2017, 17, 898-904.	1.1	3
48	EpCAM-positive circulating tumor cells as liquid biomarker for early micrometastases and HCC recurrence risk. Journal of Hepatology, 2017, 66, S457.	3.7	2
49	Polymorphisms of the human platelet antigen-1, -2, -3, -5, and -15 systems and acute cellular liver transplant rejection. Human Immunology, 2017, 78, 534-539.	2.4	4
50	Hobit expression by a subset of human liver-resident CD56bright Natural Killer cells. Scientific Reports, 2017, 7, 6676.	3.3	37
51	Transplantation in Germany. Transplantation, 2017, 101, 213-218.	1.0	29
52	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12Amonths after resection. BMC Cancer, 2017, 17, 60.	2.6	24
53	Proliferative capacity exhibited by human liver-resident CD49a+CD25+ NK cells. PLoS ONE, 2017, 12, e0182532.	2.5	27
54	Graft-derived cell-free DNA, a noninvasive early rejection and graft damage marker in liver transplantation: A prospective, observational, multicenter cohort study. PLoS Medicine, 2017, 14, e1002286.	8.4	150

#	Article	IF	CITATIONS
55	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. Oncotarget, 2017, 8, 89978-89987.	1.8	58
56	Factors associated with long-term survival after liver transplantation: A retrospective cohort study. World Journal of Hepatology, 2017, 9, 427.	2.0	16
57	Associating liver partition and portal vein ligation for staged hepatectomy: From technical evolution to oncological benefit. World Journal of Gastrointestinal Surgery, 2016, 8, 124.	1.5	18
58	Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4. PLoS ONE, 2016, 11, e0146370.	2.5	61
59	Selection and use of immunosuppressive therapies after liver transplantation: current German practice. Clinical Transplantation, 2016, 30, 487-501.	1.6	22
60	Viral Hepatitis and Its Complications: Management of Hepatocellular Carcinoma. Visceral Medicine, 2016, 32, 127-130.	1.3	1
61	14-bp ins/del polymorphism and +3142C>G SNP of the HLA-G gene have a significant impact on acute rejection after liver transplantation. Human Immunology, 2016, 77, 1159-1165.	2.4	18
62	Course of hepatitis C virus (HCV) RNA and HCV core antigen testing are predictors for reaching sustained virologic response in liver transplant recipients undergoing sofosbuvir treatment in a real-life setting. Transplant Infectious Disease, 2016, 18, 141-145.	1.7	8
63	Fewer cytomegalovirus complications after kidney transplantation by <i>de novo</i> use of <scp>mTOR</scp> inhibitors in comparison to mycophenolic acid. Transplant Infectious Disease, 2016, 18, 79-88.	1.7	34
64	Prediction, prevention, and management of delayed graft function: where are we now?. Clinical Transplantation, 2016, 30, 1198-1208.	1.6	77
65	Treatment with MAPKAP2 (MK2) inhibitor and DNA methylation inhibitor, 5-aza dC, synergistically triggers apoptosis in hepatocellular carcinoma (HCC) via tristetraprolin (TTP). Cellular Signalling, 2016, 28, 1872-1880.	3.6	28
66	High-urgency kidney transplantation in the Eurotransplant Kidney Allocation System: success or waste of organs? The Eurotransplant 15-year all-centre survey. Nephrology Dialysis Transplantation, 2016, 31, 1515-1522.	0.7	14
67	Design and rationale of the ATHENA study – A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. Trials. 2016, 17. 92.	1.6	11
68	Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus reâ€infection after liver transplantation. Transplant Infectious Disease, 2016, 18, 326-332.	1.7	42
69	Extracellular-signal regulated kinase (Erk1/2), mitogen-activated protein kinase-activated protein kinase 2 (MK2) and tristetraprolin (TTP) comprehensively regulate injury-induced immediate early gene (IEG) response in in vitro liver organ culture. Cellular Signalling, 2016, 28, 438-447.	3.6	11
70	Depletion of three combined THOC5 mRNA export protein target genes synergistically induces human hepatocellular carcinoma cell death. Oncogene, 2016, 35, 3872-3879.	5.9	24
71	Definition of Chronic Hepatitis E After Liver Transplant Conforms to Convention. American Journal of Transplantation, 2015, 15, 3011-3012.	4.7	12
72	Regarding "Compared Efficacy of Preservation Solutions in Liver Transplantation: A Long-Term Graft Outcome Study From the European Liver Transplant Registry― American Journal of Transplantation, 2015, 15, 3272-3273.	4.7	10

#	Article	IF	CITATIONS
73	Anterior vertical miniâ€incision vs. retroperitoneoscopic nephrectomy in living kidney donation: a prospective study on donors' quality of life and clinical outcome. Clinical Transplantation, 2015, 29, 1029-1038.	1.6	3
74	Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. Journal of Cancer, 2015, 6 , $1195-1205$.	2.5	34
75	Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. Trials, 2015, 16, 118.	1.6	10
76	Is There a Role for Liver Transplantation in Non-Colorectal Liver Metastases?. Visceral Medicine, 2015, 31, 400-404.	1.3	0
77	Rat renal transplant model for mixed acute humoral and cellular rejection: Weak correlation of serum cytokines/chemokines with intragraft changes. Transplant Immunology, 2015, 33, 95-102.	1.2	5
78	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC Cancer, 2015, 15, 564.	2.6	182
79	Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cellular Signalling, 2015, 27, 2191-2200.	3.6	3
80	mTOR Inhibitors and their Role in Modern Concepts of Immunosuppression. World Journal of Surgery, 2014, 38, 3199-3201.	1.6	4
81	Induction therapy and m <scp>TOR</scp> inhibition: minimizing calcineurin inhibitor exposure in <i>de novo</i> renal transplant patients. Clinical Transplantation, 2013, 27, 16-29.	1.6	13
82	Wound Healing Complications and the Use of Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation. Transplantation, 2012, 94, 547-561.	1.0	138